CXCL10 anticorps (Biotin)

N° du produit ABIN2661156

Détail du produit anti-CXCL10 anticorps (Biotin)

Antigène: CXCL10 (Chemokine (C-X-C Motif) Ligand 10 (CXCL10))

Reactivité: Humain

Hôte: Chèvre

Clonalité: Polyclonal

Conjugué: Cet anticorp CXCL10 est conjugé à/à la Biotin

Application: Flow Cytometry (FACS)

Purification: The antibody was purified by affinity chromatography, and conjugated with biotin under optimal conditions. The solution is free of unconjugated biotin.

Clone: Poly5194

Isotype: IgG

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Concentration: 0.5 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Do not freeze.

Stock: 4 °C

Stockage commentaire: The antibody solution should be stored undiluted between 2°C and 8°C.

Détails sur CXCL10

Antigène: CXCL10 (Chemokine (C-X-C Motif) Ligand 10 (CXCL10))

Autre désignation: CXCL10 (CXCL10 Produits)

Synonymes: anticorps CXCL10, anticorps C7, anticorps IFI10, anticorps INP10, anticorps IP-10, anticorps SCYB10, anticorps crg-2, anticorps gIP-10, anticorps mob-1, anticorps CRG-2, anticorps IP10, anticorps Ifi10, anticorps Scyb10, anticorps C-X-C motif chemokine ligand 10, anticorps C-X-C motif chemokine 10, anticorps chemokine (C-X-C motif) ligand 10, anticorps CXCL10, anticorps cxl10, anticorps Cxcl10

Sujet: CXCL10 is an ELR-negative chemokine structurally and functionally related to CXCL9 and CXCL11. CXCL10, CXCL9, and CXCL11 are produced and secreted by monocytes, macrophages, fibroblasts, and epithelial cells upon stimulation with proinflammatory cytokines, especially IFNγ. CXCL10 chemoattracts CD4, CD8, and NK and NKT cells through the binding to its receptor CXCR3, which is shared with CXCL9 and CXCL11. In addition, CXCL10 inhibits neovascularization in tumors and in wound healing in vivo. Also, CXCL10 has anti-proliferative effects on endothelial cells in vitro, and angiostatic and antitumor effects in vivo. It has been suggested that the anti-proliferative effect of CXCL10 in endothelial cells is CXCR3-independent and that it is mediated through GAG interaction. CXCL10 also possesses antimicrobial activity against E. coli and L. monocytogenes, and both the spore and bacillus forms of B. anthracis. CXCL10 expression is strongly upregulated in many human inflammatory diseases, including rheumatoid arthritis, type I diabetes, multiple sclerosis, atherosclerosis, allograft rejection, and others.